Compare WOLF & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOLF | DRTS |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2025 | 2021 |
| Metric | WOLF | DRTS |
|---|---|---|
| Price | $26.38 | $14.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $25.00 | $17.80 |
| AVG Volume (30 Days) | ★ 3.3M | 476.5K |
| Earning Date | 11-04-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | N/A |
| Revenue This Year | $14.87 | N/A |
| Revenue Next Year | $4.07 | $1,235.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $13.49 | $3.43 |
| 52 Week High | $80.82 | $15.79 |
| Indicator | WOLF | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 54.88 |
| Support Level | $23.31 | $13.73 |
| Resistance Level | $26.70 | $15.23 |
| Average True Range (ATR) | 2.23 | 0.65 |
| MACD | 0.19 | 0.14 |
| Stochastic Oscillator | 95.42 | 82.98 |
Wolfspeed Inc is an innovator of wide bandgap semiconductors, focused on silicon carbide materials and devices for power applications. Its product families include silicon carbide materials and power devices. Its products are targeted for various applications in the Automotive domain, including electric vehicles and fast charging, as well as existing and emerging applications in the Industrial & Energy domain such as AI data centers, grid modernization and renewable energy and storage as well as aerospace and defense. The company also use contract manufacturers, some of which include captive lines, for certain products and aspects of product fabrication, assembly and packaging. The company has one reportable segment. Majority of revenue comes from United States followed by Hong Kong.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.